Elevated TNFR1 and Serotonin in bone metastasis is correlated with poor survival 1 following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. 
INTRODUCTION

85
There is an urgent need to develop novel and reliable molecular targets for the prognosis and 
MATERIALS
111
The biospecimens used for this study were snap frozen portions of bone metastasis collected over 112 a 10 year period from a variety of primary tumors, including some rare categories of primary 113 tumors (Table 1) . 159 bone metastases specimens from a spectrum of primary carcinomas and 114 primary sarcomas (Table 1 and Supplementary Table S1 ) were collected at the Istituto snap-frozen, maintained at -80°C and thawed once for analysis.
121
Frozen bone metastasis samples were divided into two pieces. One piece was thawed/fixed in 122 10% formalin, decalcified in formic/nitric acid and paraffin-embedded (FFPE) to evaluate the 123 tumor cell percentage. The second piece was lysed using Adaptive Focused Acoustic (AFA™) 124 technology (Covaris) to quantify the levels of 88 proteins by RPMA.
125
We have recently developed a novel fixation method for decalcification of bone and preservation 126 of proteins (13) . This fixative was used for immunohistochemical examination of serotonin in 127 example bone metastasis cases material from recently diagnosed cases that were not part of the 128 159 bone metastasis cases described above with 10 year followup.
129
Survival under standard of care therapy was defined as the number of months from the first 130 diagnosis of bone metastasis. (Supplementary Table S1 
Statistical Methods
172
The Kruskal-Wallis one-way analysis of variance (GraphPad Prism v5.03 (GraphPad Software,
173
Inc.)) was applied to the 5 groups of bone metastasis specimens from different primary tumors of 174 origin, using the median of the intensities for each group and to compare TNFR1 expression 175 levels across the 4 patient groups identified by the survival quartiles. The Mann-Whitney t test 176 on medians (GraphPad) was used to compare a) protein expression levels in metastases 177 colonized from primary sarcomas with metastases derived from primary carcinomas, b) TNFR1 178 expression levels in long and short term survivors and c) sample age in patients with high and 179 low TNFR1 expression levels. p0.05 was considered significant.
180
The Kaplan-Meier product limit estimator (GraphPad) was applied to bone metastasis survival Research. Table S1 ). The training (n=72) and validation sets (n=71) were randomly The Mann-Whitney t test between the top and bottom quartiles showed a significant difference in 297 TNFR1 expression in the 2 groups (p=0.0009). (Figure 4A ). In all cases combined (n=143), codependence between primary site and TNFR1. Nonetheless, the median TNFR1 level was 317 higher in bone metastases from sarcomas when compared to those from all types of carcinomas.
318
A possible explanation is that the survival range of patients in the primary sarcoma group (2-42 319 months) was much shorter than that of patients in the primary carcinoma group (0-98 months).
320
Age at diagnosis, sex, site of metastasis, number of bone metastases and number of total 321 metastases at follow-up were investigated for their potential correlation with the patients'
322
Research. 
survival. None of these parameters was related to survival by Kaplan-Meier's analysis (p>0.05).
323
With univariate analysis, p values for the number of bone metastases and the number of total 324 metastases in all organs were p0.2, therefore these 2 variables were included in the multivariate We also investigated whether the sample specimen age was correlated with TNFR1 expression 329 level. The Mann-Whitney t test applied to the median TNFR1 levels of the 25th and 75th 330 quartiles was not significantly different providing additional support to the finding that TNFR1 331 was independent of common prognostic factors or specimen collection/specimen age. (Figures 2 and 3) . These results suggest that TNFR1 341 signaling couples with the neuroendocrine signaling to promote bone metastasis aggressiveness.
342
Second independent validation conducted using SVM. Table S7 ) 358 We used SVM classification with two validation algorithms, 10-fold-CV and jackknife test
359
(leave-one-out CV (LOOCV)).LOOCV is the only method that is deterministic and displays low To test the baseline bias we randomly reshuffled the class labels in several sets: in all the cases 366 the resulting accuracy closely matched the expected 50% from random guessing. Since all the 367 sets were balanced, accuracy rates and AUC strongly correlated. AUCs calculated using LOOCV Table S7 )) display protein expression patterns characteristic of the class S and that the boundary 376 between class S and L is located near the 28 month point on the survival time scale.
377
SVM ranking confirms the training set data
378
To determine the relative contribution of the 88 end-point expression profiles to the SVM 379 discriminating power, we ranked the proteins using the attribute evaluator program Table   387 2). Set BM45 was selected because it was the largest set with the highest AUC (Supplementary 
438
The role of TNFR1 and Serotonin was confirmed in two different validation methods. In addition A weakness of our study is that we cannot know the subcellular localization of proteins we have 447 measured in the bone metastasis microenvironment. We are using bone metastasis specimens These data also reveal an unexpected role for the neuroendocrine pathways in bone metastasis. 
501
We hypothesize that TNFR1 and Serotonin participate in the cross-talk between the tumor cells 502 and the bone microenvironment in a manner that is independent of the primary tumor of origin.
503
These data support a model of "seed vs. soil" in which a common set of signaling pathways 504 permit the metastasis to target and flourish in the bone, regardless of the primary tumor of origin.
505
We hypothesize that a combined therapy targeting TNFR1 and Serotonin could improve the Supplementary Table S1 . 
682
In all four graphs survival is defined as the number of months each patient survived following 683 the first diagnosis of bone metastasis.
684
A) The total set of 143 samples with known survival data was subdivided into 4 quartiles base on 
